Discontinuation due to adverse reactions in the PHN clinical trial¹

The pharmacokinetics of Horizant^® were compared with those of conventional gabapentin in a crossover study of the same healthy adults. Patients (N=12) were randomized to 3 different treatment sequences, each receiving 3 doses: a 626 mg gabapentin-equivalent dose of Horizant^® with food, a 626 mg gabapentin-equivalent dose of Horizant^® without food, and a 600 mg dose of conventional gabapentin without food. Patients had a 7-day washout period between doses. Data for fasted state are not available, as Horizant^® Prescribing Information states that it should be taken with food.